|

Mixing Psychedelics & Antidepressants: Is it Safe? | NEW Psilocybin Study

ByPsychedelic Spotlight

As using psychedelics as medicines for mental health conditions has become more popular, it has been an open question of whether substances such as psilocybin (magic mushrooms) can safely be combined with anti-depressants such as SSRIs.
Now, Compass Pathways (CMPS) has released a small study, which showed that it is in fact safe to combine the two drugs. This is the second such small study to come to this conclusion. Earlier this year, MindMed, (MNMD / MMED) had released data on a similar study, with similar results
However, it is important to note that these are two very small studies, and that nothing has been definitively proven yet.
Many argue that psychedelics like psilocybin should be a replacement for depression medications such as SSRIs, not another layer of medicine. While I am sympathetic to this view, we must ultimately follow the science.
Compass Pathways will use the results of this trial to inform the design of their upcoming phase 3 trial testing whether psilocybin can treat treatment resistant depression.
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy
@Psychedelic Spotlight

#psychedelics #antidepressants #psilocybin

Similar Posts

  • Field Trip And Wesana Make Major Moves | FTRP, WESA

    Listen, Videos

    Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd:
    www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20

    Join our Newsletter (scroll to the bottom of the page and sign up):
    https://psychedelicspotlight.com/

    Wesana Health May Sell Clinics to Focus Solely on Drug Development: An Analysis
    https://psychedelicspotlight.com/wesana-health-may-sell-clinics-to-focus-solely-on-drug-development-an-analysis/

    Why Field Trip Health Is Dividing in Two — and What This Means for Investors
    https://psychedelicspotlight.com/field-trip-health-dividing-two-companies-reunion-neuroscience/

    In today’s episode of the Psychedelic Investor, I discuss two major stories. First, is the news that Field Trip Health (Nasdaq: FTRP, TSX: FTRP) will be splitting into two separate companies.
    Next, Wesana Health (CSE: WESA, OTCQB: WSNAF) announced that they are considering selling all of their non-drug development assets, including their Psychedelic Therapy clinics.

    Follow us on Twitter:
    James: @Psy_Invest
    Maria: @psy_holy
    The Psychedelic Investor: @PSYCBiz
    Psychedelic Spotlight: @PsycSpotlight
    Follow us on Instagram:
    @psycbiz
    @psycspotlight

    To read more about the Field Trip situation: https://psychedelicspotlight.com/field-trip-health-dividing-two-companies-reunion-neuroscience/

    To read more about the Wesana situation: https://psychedelicspotlight.com/wesana-health-may-sell-clinics-to-focus-solely-on-drug-development-an-analysis/

    Field Trip Press Release: https://www.globenewswire.com/news-
    release/2022/04/28/2432105/0/en/Field-Trip-Health-Ltd-Announces-Intention-to-Separate-the-Field-Trip-Discovery-and-Field-Trip-Health-Divisions-Into-Two-Independent-Public-Companies.html
    Wesana Press Release: https://ir.wesanahealth.com/news-events/press-releases/detail/41/wesana-announces-singular-focus-on-drug-development

    Field Trip Health:
    In a surprise move, Field Trip Health Ltd. announced on Thursday that they will be separating their company into two independent publicly traded entities.
    Assuming the ratification of shareholders and regulatory approval, come July 2022, Field Trip Health will be no more. From its ashes will rise Reunion Neuroscience Inc, and Field Trip Health and Wellness Ltd.
    Reunion will be the successor to Field Trip’s Discovery division, which was the part of the company which worked on next-generation psychedelics. This includes FT-104, a psilocybin-like compound that is a prodrug to 4-HO-DiPT, and the company’s FT-200 series of psychedelics, which they call third-generation.

    Wesana:
    On Thursday, Wesana Health made a major announcement. Following a planned strategic review of their assets, Wesana is considering options “including, but not limited to, a sale of all the assets under the care delivery division,” including all of their psychedelic therapy clinics.
    The core reasoning, according to the press release, is that Wesana wants to focus its efforts entirely on its drug development division.
    Prior to this announcement, Wesana was operating under a philosophy centered on “developing the novel therapies of tomorrow and delivering new care paradigms today.” If this strategic review does result in the sale of their clinics and other today-focused ventures, then Wesana will be decidedly much more focused on tomorrow.

    @psycspotlight #wesana #psychedelicstocks #thepsychedelicinvestor

  • Interview with Patrick Moher, CEO of Microdose

    Interviews, Listen, Podcasts

    In this chat, he discusses some of the challenges involved in moving virtual events to an in-person conference (during a pandemic), who and what to expect at the event, and why Wonderland Miami is not just any other conference, but a one-of-a-kind experience.Â